FCA
DMAC icon

FinTrust Capital Advisors’s DiaMedica Therapeutics DMAC Stock Holding History

FinTrust Capital Advisors’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-75
Closed – – 1231
2022
Q1 		$0 Hold
75
– – ﹤0.01% 1237
2021
Q4 		$0 Buy
+75
New +$294 ﹤0.01% 1201

Other funds holding DMAC

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FinTrust Capital Advisors's DMAC Position: Q2 2022 in Review

FinTrust Capital Advisors sold out of DiaMedica Therapeutics (DMAC) in Q2 2022, closing a stake of 75 shares.

FinTrust Capital Advisors first reported a position in DMAC in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 28 funds tracked by Wall St. Rank hold DMAC as of Q2 2022.

  • FinTrust Capital Advisors reported no remaining DiaMedica Therapeutics position as of Q2 2022 after selling out during the quarter.
  • FinTrust Capital Advisors sold 75 DiaMedica Therapeutics shares in Q2 2022.
  • FinTrust Capital Advisors first reported a position in DiaMedica Therapeutics in Q4 2021 and held it in 2 quarters.
  • FinTrust Capital Advisors's DiaMedica Therapeutics position peaked at $0 in Q1 2022.
  • 28 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2022.

Based on FinTrust Capital Advisors's 13F filing for Q2 2022, filed 26 Jul 2022.